Glioblastomas are difficult to treat, and patients have a poor prognosis. Knowledge of the molecular pathogenesis of glioma has launched an era of targeted-therapies, which are discussed in this Review article. Biomarkers, novel trial design, and the identification of molecular subgroups are other advances that are explored here.
- Shota Tanaka
- David N. Louis
- Jorg Dietrich